Form PTO-1595 RECORDATION FOR	####				
(Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002)  PATENTS ONLY  101900738					
Tab settings	TO 1900738				
	Please record the attached original documents or copy thereof.				
Name of conveying party(ies):	Name and address of receiving party(ies)				
11-20-0   2020, 0	Name: PEG INTRACEL LENDING CO. LLC				
INTRACEL CORPORATION	Internal Address: <u>c/o Pegasus Investors</u>				
Additional name(s) of conveying party(ies) attached? Yes No					
3. Nature of conveyance:					
🖬 Assignment 📮 Merger	Street Address: 99 River Road				
Security Agreement	onostriudioss. 23 kilvei koad				
Other					
	City: Cos Cob State: CT Zip: 06807-25				
Execution Date: November 15, 2001	Additional name(s) & address(es) attached? 📮 Yes 🚨 No				
4. Application number(s) or patent number(s):					
If this document is being filed together with a new app	ication, the execution date of the application is:				
A. Patent Application No.(s)	B. Patent No.(s)				
08/540,298	5,484,596				
Additional numbers a	ttached? Yes 📮 No				
5. Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 53				
Name: Noel D. Humphreys	7. Total fee (37 CFR 3.41)\$ <u>2,120.00</u>				
Internal Address:	⊑ Enclosed				
Aking, Gump, Strauss, Hauer & Feld, LLP	Authorized to be charged to deposit account				
	8. Deposit account number:				
Street Address: 590 Madison Avenue					
	50-1972				
Suite 1800					
City: New York State: NY Zip: 10022	(Attach duplicate copy of this page if paying by deposit account)				
DO NOT US	E THIS SPACE				
Statement and signature.					
To the best of my knowledge and belief, the foregoing	information is true and correct and any attached copy				
is a true copy of the original document.  Noel D. Humphreys	11 Defum Hug 11-19-01				
Name of Person Signing	Signature () () Date				
2001 DBYRME 00000049 501972 Total FACE PAGE of pages including cover sheet, attachments, and documents:					
581 2120.00 CH Mail documents to be recorded with Commissioner of Patents &	h required cover sheet information to: Trademarks, Box Assignments n, D.C. 20231				

## **Recordation Form Cover Sheet PATENT ONLY Continuation Page**

## Question No. 1:

INTRACEL NETHERLANDS, B.V., a Netherlands Corporation

HUMAN ANTIBODY SCIENCES, INC., a Delaware Corporation

PERIMMUNE, INC., a Delaware Corporation

PERIMMUNE HOLDINGS, INC., a Delaware Corporation



288265 v1 Page 2

# **Recordation Form Cover Sheet PATENTS ONLY Continuation Page**

# **Question No. 4:**

PATENTS ISSUED	
OncoVAX	
Active Specific Immonotherapy	5,484,596
Tumor Associated Monoclonal Antibody	5,348,880
·	5,474,755
Tumor Specific Monoclonal Antibodies	4,828,991
•	4,997,762
	5,106,738
	5,180,814
CTAA 28A32, The Antigen Recognized by MCA 28A32	5,521,285
Tumor Associated Monoclonal Antibody 123AV16	5,495,002
In vitro method for producing antigen-specific human monoclonal antibodies	5,229,275
Imaging Infectious Foci With Human IgM 16-88	5,840,272
	· · · · · · · · · · · · · · · · · · ·
KLH	
Method of Treating Bladder Cancer with a Keyhole	5,407,912
Limpet Hernocyanin Composition with Enhanced Anti-	5,855,919
Tumor Activity	5,981,476
Leukoregulin	
Leukoregulin, An Antitumor Lymphokine, and its	5,082,657
Therapeutic Uses	
Human Antibody Science	
In Vivo Binding Pair Pretargeting	5,965,106
In Vivo Binding Pair Pretargeting	5,807,534
	5,578,289
Method for Purifying Chelator Conjugated Compounds	5,244,816
Macrocyclic chelating agent	5,583,219
Tumor Associated Epitopes	5,951,985
Antigen Recognized by MCA 16-88	5,338,832
Antigen Recognized by MCA 10-00	2,220,022
Technetium-99m Labeling of Proteins	5,317,091
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator	
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds	5,317,091
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin	5,317,091 5,800,802
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin Oligomets	5,317,091 5,800,802
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin Oligomets Polymer Affinity Systems For the Delivery of Cytotoxic	5,317,091 5,800,802 5,705,634
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin Oligomets Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease	5,317,091 5,800,802 5,705,634 5,686,071
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin Oligomets Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease	5,317,091 5,800,802 5,705,634 5,686,071 5,549,882
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin Oligomets Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Imaging Infectious Foci With Human IgM 16-88	5,317,091 5,800,802 5,705,634 5,686,071 5,549,882 5,840,272
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin Oligomets Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Imaging Infectious Foci With Human IgM 16-88 Site Specific In Vivo Activation of Therapeutic Drugs	5,317,091 5,800,802 5,705,634 5,686,071 5,549,882 5,840,272 5,433,955
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin Oligomets Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Imaging Infectious Foci With Human IgM 16-88 Site Specific In Vivo Activation of Therapeutic Drugs Radial flow assay, delivering member, test kit and	5,317,091 5,800,802 5,705,634 5,686,071 5,549,882 5,840,272
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin Oligomets Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Imaging Infectious Foci With Human IgM 16-88 Site Specific In Vivo Activation of Therapeutic Drugs Radial flow assay, delivering member, test kit and methods	5,317,091 5,800,802 5,705,634 5,686,071 5,549,882 5,840,272 5,433,955 5,547,833
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin Oligomets Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Imaging Infectious Foci With Human IgM 16-88 Site Specific In Vivo Activation of Therapeutic Drugs Radial flow assay, delivering member, test kit and methods Detection reagent article, and immunoassay method	5,317,091 5,800,802 5,705,634 5,686,071 5,549,882 5,840,272 5,433,955 5,547,833 5,561,045
Technetium-99m Labeling of Proteins Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds High Yield Preparation of Dimeric to Decameric Chitin Oligomets Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Imaging Infectious Foci With Human IgM 16-88 Site Specific In Vivo Activation of Therapeutic Drugs Radial flow assay, delivering member, test kit and	5,317,091 5,800,802 5,705,634 5,686,071 5,549,882 5,840,272 5,433,955 5,547,833

Antibodies to APO(A)  Polyaminocarboxylate chelators Chelating agent for attaching metal ions to proteins CTAA 81AV78, the antigen recognized by human monoclonal antibody 81AV78  CTAA 81AV78, the antigen recognized by human monoclonal antibody 81AV78  Alignment system to overlay abdominal computer-aided tomography and magnetic resonance anatomy with single photon enhanced tomography Urethral catheter and catheterization process Leukoregulin, an antitumor lymphokine, and its therapeutic uses  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy Monoclonal antibody 88BV59  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity Tumor Associated Epitopes Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated Compounds  5,292,868 5,292,86 5,292,868 5,292,868 5,292,868 5,292,868 5,292,868 5,292,868 5,2		
Chelating agent for attaching metal ions to proteins CTAA 81AV78, the antigen recognized by human monoclonal antibody 81AV78 CTAA 81AV78, the antigen recognized by human monoclonal antibody 81AV78 Alignment system to overlay abdominal computer-aided tomography and magnetic resonance anatomy with single photon enhanced tomography Urethral catheter and catheterization process Leukoregulin, an antitumor lymphokine, and its therapeutic uses  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy Monoclonal antibody 88BV59 Monoclonal antibody 88BV59 KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity Tumor Associated Epitopes Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  5,299,253 5,488,126 5,299,253	Antibodies to APO(A)	5,874,544
CTAA 81AV78, the antigen recognized by human monoclonal antibody 81AV78 CTAA 81AV78, the antigen recognized by human 5,488,126 monoclonal antibody 81AV78 Alignment system to overlay abdominal computer-aided tomography and magnetic resonance anatomy with single photon enhanced tomography Urethral catheter and catheterization process 5,120,316 Leukoregulin, an antitumor lymphokine, and its 4,849,506 therapeutic uses  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy 08/540,298 Monoclonal antibody 88BV59 08/341469  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti-Tumor Activity Tumor Associated Epitopes 08/478,591 Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs 08/382,469  InVitro Diagnostics  Neutralizing Monoclonal Antibodies to Respiratory 09/043,522 Synctial Virus 09/043,530 Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to 60/258,504	The state of the s	
monoclonal antibody 81AV78  CTAA 81AV78, the antigen recognized by human monoclonal antibody 81AV78  Alignment system to overlay abdominal computer-aided tomography and magnetic resonance anatomy with single photon enhanced tomography  Urethral catheter and catheterization process  Leukoregulin, an antitumor lymphokine, and its therapeutic uses  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy 08/540,298  Monoclonal antibody 88BV59 08/341469  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti-Tumor Activity Tumor Associated Epitopes 08/478,591  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease  Site Specific In Vivo Activation of Therapeutic Drugs 08/382,469  InVitro Diagnostics  Neutralizing Monoclonal Antibodies to Respiratory 99/043,530  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to 60/258,504  Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated 08/278,721		
CTAA 81AV78, the antigen recognized by human monoclonal antibody 81AV78  Alignment system to overlay abdominal computer-aided tomography and magnetic resonance anatomy with single photon enhanced tomography Urethral catheter and catheterization process 5,120,316  Leukoregulin, an antitumor lymphokine, and its 4,849,506 therapeutic uses  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy 08/540,298 Monoclonal antibody 88BV59 08/341469  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti-Tumor Activity Tumor Associated Epitopes 08/478,591 Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs 08/382,469  InVitro Diagnostics Neutralizing Monoclonal Antibodies to Respiratory 99/043,522 Synctial Virus 09/043,530 Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721	, , ,	5,595,738
Alignment system to overlay abdominal computer-aided tomography and magnetic resonance anatomy with single photon enhanced tomography  Urethral catheter and catheterization process  Leukoregulin, an antitumor lymphokine, and its therapeutic uses  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy  Monoclonal antibody 88BV59  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti-Tumor Activity  Tumor Associated Epitopes  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  5,299,253  5,299,253  5,299,253  5,299,253  5,299,253  6		
Alignment system to overlay abdominal computer-aided tomography and magnetic resonance anatomy with single photon enhanced tomography  Urethral catheter and catheterization process  Leukoregulin, an antitumor lymphokine, and its therapeutic uses  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy 08/540,298  Monoclonal antibody 88BV59 08/341469  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti-Tumor Activity  Tumor Associated Epitopes 08/478,591  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs 08/382,469  InVitro Diagnostics  Neutralizing Monoclonal Antibodies to Respiratory 09/043,522 Synctial Virus 09/043,530  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated 08/278,721		5,488,126
tomography and magnetic resonance anatomy with single photon enhanced tomography  Urethral catheter and catheterization process  Leukoregulin, an antitumor lymphokine, and its therapeutic uses  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy 08/540,298  Monoclonal antibody 88BV59 08/341469  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti-Tumor Activity  Tumor Associated Epitopes 08/478,591  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease  Site Specific In Vivo Activation of Therapeutic Drugs 08/382,469  InVitro Diagnostics  Neutralizing Monoclonal Antibodies to Respiratory 09/043,530  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to 60/258,504  Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated 08/278,721		
PATENTS APPLIED FOR  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy 08/540,298 Monoclonal antibody 88BV59 08/341469  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti-Tumor Activity Tumor Associated Epitopes 08/478,591 Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs 08/382,469  InVitro Diagnostics Neutralizing Monoclonal Antibodies to Respiratory 09/043,522 Synctial Virus 09/043,530 Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to 60/258,504 Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721		5,299,253
Urethral catheter and catheterization process  Leukoregulin, an antitumor lymphokine, and its therapeutic uses  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy Monoclonal antibody 88BV59 Monoclonal antibody 88BV59 Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity Tumor Associated Epitopes Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus O9/043,522 O9/043,530 Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated  08/278,721		
Leukoregulin, an antitumor lymphokine, and its therapeutic uses  PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy 08/540,298 Monoclonal antibody 88BV59 08/341469  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti-Tumor Activity  Tumor Associated Epitopes 08/478,591  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease  Site Specific In Vivo Activation of Therapeutic Drugs 08/382,469  InVitro Diagnostics  Neutralizing Monoclonal Antibodies to Respiratory 09/043,530  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated 08/278,721		
PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy 08/540,298 Monoclonal antibody 88BV59 08/341469  KLH  Method of Treating Bladder Cancer with a Keyhole 108/343,808 Limpet Hernocyanin Composition with Enhanced Anti-108 Tumor Activity Tumor Associated Epitopes 08/478,591 Polymer Affinity Systems For the Delivery of Cytotoxic 108/937,558 Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs 08/382,469  InVitro Diagnostics  Neutralizing Monoclonal Antibodies to Respiratory 09/043,530 Human Monoclonal Antibodies Specific for Activated 09/225,647 CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721		<del></del>
PATENTS APPLIED FOR  OncoVAX  Active Specific Immonotherapy 08/540,298 Monoclonal antibody 88BV59 08/341469  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity  Tumor Associated Epitopes 08/478,591  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease  Site Specific In Vivo Activation of Therapeutic Drugs 08/382,469  InVitro Diagnostics  Neutralizing Monoclonal Antibodies to Respiratory 09/043,522 Synctial Virus 09/043,530  Human Monoclonal Antibodies Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to 60/258,504  Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated 08/278,721	· · ·	4,849,506
Active Specific Immonotherapy  Monoclonal antibody 88BV59  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity  Tumor Associated Epitopes  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease  Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus  109/043,530  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  08/278,721	therapeutic uses	
Active Specific Immonotherapy  Monoclonal antibody 88BV59  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity  Tumor Associated Epitopes Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  InVitro Diagnostics  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated  08/343,808  08/343,808  08/343,808  08/343,808  08/343,808  08/343,808  08/937,558  08/937,558  08/937,558  08/937,558  08/937,558  08/937,558  08/937,558  60/258,504	PATENTS APPLIED FOR	
Monoclonal antibody 88BV59  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity  Tumor Associated Epitopes  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  08/278,721	OncoVAX	
Monoclonal antibody 88BV59  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity  Tumor Associated Epitopes  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  08/278,721		
Monoclonal antibody 88BV59  KLH  Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity  Tumor Associated Epitopes  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  08/278,721	Active Specific Immonotherapy	08/540,298
Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity  Tumor Associated Epitopes Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated  08/343,808 08/343,808 08/478,591 08/478,591 08/937,558 09/043,530 0		08/341469
Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity  Tumor Associated Epitopes  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease  Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus  Neutralizing Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  08/278,721	KLH	
Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity  Tumor Associated Epitopes  Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease  Site Specific In Vivo Activation of Therapeutic Drugs  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus  Neutralizing Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  08/278,721	Method of Treating Bladder Cancer with a Keyhole	08/343,808
Tumor Activity Tumor Associated Epitopes 08/478,591 Polymer Affinity Systems For the Delivery of Cytotoxic 08/937,558 Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs 08/382,469  InVitro Diagnostics Neutralizing Monoclonal Antibodies to Respiratory 09/043,522 Synctial Virus 09/043,530 Human Monoclonal Antibodies Specific for Activated 09/225,647 CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to 60/258,504 Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721		
Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  1nVitro Diagnostics Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus 09/043,522 99/043,530 Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721		
Polymer Affinity Systems For the Delivery of Cytotoxic Materials and Other Compounds to Site of Disease Site Specific In Vivo Activation of Therapeutic Drugs  1nVitro Diagnostics Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus 09/043,522 Synctial Virus 09/043,530 Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721	Tumor Associated Epitopes	08/478,591
Materials and Other Compounds to Site of Disease  Site Specific In Vivo Activation of Therapeutic Drugs  1nVitro Diagnostics  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus 09/043,522 Synctial Virus 09/043,530  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721		08/937,558
InVitro Diagnostics  Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus  Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated  08/278,721		
Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus 09/043,530 Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721		08/382,469
Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus 09/043,530 Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721		
Neutralizing Monoclonal Antibodies to Respiratory Synctial Virus 09/043,530 Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721	InVitro Diagnostics	
Synctial Virus 09/043,530  Human Monoclonal Antibodies Specific for Activated 09/225,647  CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated 08/278,721		09/043,522
Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  09/225,647  60/258,504	• • • • • • • • • • • • • • • • • • •	09/043,530
CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  08/278,721		09/225,647
and Methods of Use Thereof  Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated  08/278,721		
Human CD20 Antigen  Chelator and Method for Purifying Chelator Conjugated 08/278,721		
Human CD20 Antigen Chelator and Method for Purifying Chelator Conjugated 08/278,721	Human Monoclonal Antibodies and Derived Mimetics to	60/258,504
Chelator and Method for Purifying Chelator Conjugated 08/278,721	Human CD20 Antigen	-
		08/278,721

#### PATENT SECURITY AGREEMENT

(Patents, Patent Applications and Patent Licenses)

WHEREAS, Intracel Corporation, a Delaware corporation ("Intracel-Delaware"), and Intracel Netherlands B.V., a Netherlands corporation ("Intracel-Netherlands") are the borrowers under that certain Secured Super-Priority Debtor in Possession Credit Agreement dated as of October 31, 2001 (the "Credit Agreement"); and

WHEREAS, Human Antibody Sciences, Inc. ("HASI"), PerImmune Holdings, Inc. ("PH"), and PerImmune, Inc. (PerImmune"), each a Delaware corporation, have agreed to guarantee the obligations of Intracel-Delaware and Intracel-Netherlands under the Credit Agreement; and

WHEREAS, Intracel-Delaware, Intracel-Netherlands, HASI, PH, and Perlmmune are collectively referred to in this Patent Security Agreement as the "Lien Grantor"; and

WHEREAS, in (i) the Credit Agreement, and (ii) certain other collateral documents (including this Patent Security Agreement), the Lien Grantor has granted and/or is granting to PEG Intracel Lending Co. LLC (the "Grantee") for Grantee's benefit a continuing security interest in personal property of the Lien Grantor, including all right, title and interest of the Lien Grantor in, to and under the Patent Collateral (as defined below), to secure the Lien Grantor's Obligations (as defined in the Credit Agreement);

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Lien Grantor grants to the Grantee, to secure the Lien Grantor's Obligations (as defined in the Credit Agreement), a continuing security interest in all of the Lien Grantor's right, title and interest in, to and under the following (all of the following items or types of property being herein collectively referred to as the "Patent Collateral"), whether now owned or existing or hereafter acquired or arising:

- a) each Patent (as defined in the Credit Agreement) owned by the Lien Grantor, including, without limitation, each Patent referred to in Schedule 1 hereto;
- b) each Patent License (as defined in the Credit Agreement) to which the Lien Grantor is a party, including, without limitation, each Patent License identified in Schedule 1 hereto; and
- c) all proceeds of and revenues from the foregoing, including, without limitation, all proceeds of and revenues from any claim by the Lien Grantor against third parties for past, present or future infringement of any Patent owned by the Lien Grantor (including, without limitation, any Patent License identified in Schedule 1 hereto).

The Lien Grantor irrevocably constitutes and appoints the Grantee and any officer or agent thereof, with full power of substitution, as its true and lawful attorney-in-fact with full

Page 5

032084.0022 NEW YORK 285115 v7

power and authority in the name of the Lien Grantor or in the Grantee's name, from time to time, in the Grantee's discretion, to take with respect to the Patent Collateral any and all appropriate action that the Lien Grantor might take with respect to the Patent Collateral and to execute any and all documents and instruments that may be necessary or desirable to carry out the terms of this Patent Security Agreement and to accomplish the purposes hereof.

Except to the extent expressly permitted in the Credit Agreement, the Lien Grantor agrees not to sell, license, exchange, assign or otherwise transfer or dispose of, or grant any rights with respect to, or mortgage or otherwise encumber, any of the Patent Collateral.

The foregoing security interest is granted in conjunction with the security interests granted by the Lien Grantor to the Grantee pursuant to the Credit Agreement. The Lien Grantor acknowledges and affirms that the rights and remedies of the Grantee with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Credit Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

[Signature pages follow]

Page 6

032084.0022 NEW YORK 285115 v7

IN WITNESS WHEREOF, the Lien Grantor has caused this Patent Section has duly appeared by the section of the sec	
to be duly executed by its officer thereunto duly authorized as of the Notice 1, 2001.	day of
, 2001.	
INTRAÇEL CORPORATIO	N
By:	
Name: Plan &C 1/wDS49	<i>f</i>
Name: CHARLES LINDSAY Title: PRES.	
Fice P	
Acknowledged:	
By:	
Name:	
Title: Secretary	
STATE OF CONNECTION )  COUNTY OF FAMPRICE )  ss:	
STATE OF CONNECTION )	
SS:	
COUNTY OF PHICIECY	
Notary Public in and for said County, in the State afores	raid DO
I,, a Notary Public in and for said County, in the State afores HEREBY CERTIFY, that, [ ] of Intracel Corpor	ation (the
"Company"), personally known to me to be the same person whose name is subscribed.	ribed to the
foregoing instrument as such [ ], appeared before me this day in person and ack	
he signed, executed and delivered the said instrument as his own free and voluntar	
the free and voluntary act of said Company, for the uses and purposes therein set f	-
authorized so to do.	_ ,
GIVEN under my hand and Notarial Seal this $\underline{\mathcal{V}}$ day of November, 2003	1.
[Seal]	
Janes O. Rulla	
Signature of notary public	
My Commission expires	
Notary Public	
[Signature page 10 Fight Security Agreement]	
AND MORE TO SEE	

## INTRACEL NETHERLANDS B.V.

Name: Michael G. Hanna

		Title:	Managing Director
Acknowledged:			
By: Name: Title: Secretary			
STATE OF	Maryland	)	
COUNTY OF	Montgomery	) ss: )	
aforesaid, DO HERE Intracel Netherlands same person whose [ ], appeared before executed and deliveras the free and volumest forth being duly as	EBY CERTIFY, that B.V. (the "Company name is subscribed ore me this day in perced the said instrumentary act of said Conduction authorized so to do.	r"), perso to the forson and ent as his npany, fo	r said County, in the State  [Man
[Seal]			
Shyllis le	). Wathus		
Signature of notary p My Commission expir	oublic es	Dires	

Page 8

[Signature page to Patent Security Agreement]

HUMAN ANTIBODY SCIENCES, INC.

Name: Title:

Acknowledged:
By: Name: Title: Secretary
STATE OF Maryland ) ss:  COUNTY OF Mondgomery )  Land W. Markety Public in and for said County, in the State aforesaid, BO HEREBY CERTIFY, that Markety Market
the same person whose name is subscribed to the foregoing instrument as such [ ], appeared before me this day in person and acknowledged that he signed, executed and delivered the said instrument as his own free and voluntary act and as the free and voluntary act of said Company, for the uses and purposes therein set forth being duly authorized so to do.
GIVEN under my hand and Notarial Seal this <u>1</u> 3day of November, 2001.
[Seal] Shiftis W. Wathurs
Signature of notary public My Commission Expires My Commission expiresMay 1, 2003
[Signature page to Patent Security Agreement]

Page 9

# PERIMMUNE HOLDINGS, INC.

		Title:	Chairman
Acknowledged:			
Ву:			
Name: Title: Secretary			
STATE OF	Maryland	)	
COUNTY OF	Montgomery	) ss:	
Perlmmune Holdings same person whose [ ], appeared befo executed and deliver as the free and volumet forth being duly a	s, Inc. (the "Composer in the subscriber in the subscriber in the said instruction and the said (said	pany"), personed to the for person and a ument as his Company, for do.	said County, in the State    County, in the State   County   Jof   Inally known to me to be the   legoing instrument as such   acknowledged that he signed,   own free and voluntary act and   the uses and purposes therein
[Seal] Ayllus'W. h	alpins		
Signature of notary p My Commission expire	oublic es My Condinger 1	್ಲ್ಯಾಪೀes N	

Page 10

[Signature page to Patent Security Agreement]

#### PERIMMUNE, INC.

Name: Michael G. Hanna Title: Chairman Acknowledged: By: Name: Title: Secretary Maryland STATE OF ) ss: Montgomery COUNTY OF ha a Notary Public in and for said County, in the State aforesaid, DO HEREBY CERTIFY, that Muhael S. Hanna Q Jof Perlmmune, Inc. (the "Company"), personally known to me to be the same person whose name is subscribed to the foregoing instrument as such [ appeared before me this day in person and acknowledged that he signed. executed and delivered the said instrument as his own free and voluntary act and as the free and voluntary act of said Company, for the uses and purposes therein set forth being duly authorized so to do. GIVEN under my hand and Notarial Seal this 15 day of November. 2001.

Signature of notary public

[Seal]

My Commission expireMy Commission Expires May 1, 2003

W. Walhus

[Signature page to Patent Security Agreement]

Page 11

# INTRACEL CORPORATION INTRACEL NETHERLANDS B.V. HUMAN ANTIBODY SCIENCES, INC. PERIMMUNE HOLDINGS, INC. PERIMMUNE, INC. PATENTS

#### PATENTS AND DESIGN PATENTS

United	States of Am	егіса	
OncoVAX			
Active Specific Immonotherapy	5,484,596	US	Granted
Tumor Associated Monoclonal Antibody	5,348,880	US	Granted
·	5,474,755	US	Granted
Tumor Specific Monoclonal Antibodies	4,828,991	US	Granted
•	4,997,762	US	Granted
	5,106,738	US	Granted
	5,180,814	US	Granted
CTAA 28A32, The Antigen Recognized by MCA 28A32	5,521,285	US	Granted
Tumor Associated Monoclonal Antibody 123AV16	5,495,002	US	Granted
In vitro method for producing antigen-specific human monoclonal antibodies	5,229,275	US	Granted
KLH			
Method of Treating Bladder Cancer with a Keyhole	5,407,912	US	Granted
Limpet Hernocyanin Composition with Enhanced Anti-	5,855,919	US	Granted
Tumor Activity	5,981,476	US	Granted
Leukoregulin			
Leukoregulin, An Antitumor Lymphokine, and its Therapeutic Uses	5,082,657	US	Granted
Human Antibody Science			
In Vivo Binding Pair Pretargeting	5,965,106	US	Granted
In Vivo Binding Pair Pretargeting	5,807,534	US	Granted
	5,578,289	US	Granted
Method for Purifying Chelator Conjugated Compounds	5,244,816	US	Granted
Macrocyclic chelating agent	5,583,219	US	Granted
Tumor Associated Epitopes	5,951,985	US	Granted
Antigen Recognized by MCA 16-88	5,338,832	US	Granted
Technetium-99m Labeling of Proteins	5,317,091	US	Granted
Chelator IDAC-2 and Method for Purifying Chelator Conjugated Compounds	5,800,802	US	Granted

032084.0022 NEW YORK 285115 v7

Page 12

High Yield Preparation of Dimeric to Decameric Chitin Oligomets	5,705,634	US	Granted	
Polymer Affinity Systems For the Delivery of Cytotoxic	5,686,071	US	Issued	
Materials and Other Compounds to Site of Disease				
Imaging Infectious Foci With Human IgM 16-88	5,549,882	US	Granted	
-	5,840,272	US	Granted	
Site Specific In Vivo Activation of Therapeutic Drugs	5,433,955	US	Granted	,
Radial flow assay, delivering member, test kit and	5,547,833	US	Granted	
methods				
Detection reagent article, and immunoassay method	5,561,045	US	Granted	
Immunoreactive peptides of APO(A)	5,708,138	US	Granted	
Immunoreactive peptides of APO(A)	5,786,156	US	Granted	
Immunoreactive peptides of APO(A)	5,597,908	US	Granted	
Antibodies to APO(A)	5,874,544	US	Granted	
Polyaminocarboxylate chelators	5,808,003	US	Granted	
Chelating agent for attaching metal ions to proteins	5,292,868	US	Granted	
CTAA 81AV78, the antigen recognized by human	5,595,738	US	Granted	
monoclonal antibody 81AV78				
CTAA 81AV78, the antigen recognized by human	5,488,126	US	Granted	
monoclonal antibody 81AV78				
Alignment system to overlay abdominal computer-aided	5,299,253	US	Granted	
tomography and magnetic resonance anatomy with single				
photon enhanced tomography				
Urethral catheter and catheterization process	5,120,316	US	Granted	
Leukoregulin, an antitumor lymphokine, and its	4,849,506	US	Granted	
therapeutic uses				

## PATENT APPLICATIONS

Unite	d States of Am	erica	
OncoVAX			
Active Specific Immonotherapy	08/540,298	US	Pending
Monoclonal antibody 88BV59	08/341469	US	Pending
KLH			
Method of Treating Bladder Cancer with a Keyhole Limpet Hernocyanin Composition with Enhanced Anti- Tumor Activity	08/343,808	US	Pending
Tumor Associated Epitopes	08/478,591	US	Pending
Polymer Affinity Systems For the Delivery of Cytotoxic	08/937,558	US	Pending
Materials and Other Compounds to Site of Disease	· - · <b>,</b>		
Imaging Infectious Foci With Human IgM 16-88	5,840,272	US	Pending
Site Specific In Vivo Activation of Therapeutic Drugs	08/382,469	US	Pending
InVitro Diagnostics			
Neutralizing Monoclonal Antibodies to Respiratory	09/043,522	US	Pending
Synctial Virus	09/043,530	US	Pending
Human Monoclonal Antibodies Specific for Activated CD4 Antigen, Polynucleotides Encoding the Antibodies, and Methods of Use Thereof	09/225,647	US	Pending

Page 13

Human Monoclonal Antibodies and Derived Mimetics to Human CD20 Antigen	60/258,504	US	Pending	
Chelator and Method for Purifying Chelator Conjugated Compounds	08/278,721	US	Pending	

NT

#### AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

AUSTIN
BRUSSELS
DALLAS
DENVER
HOUSTON
LONDON
LOS ANGELES
MOSCOW
NEW YORK
NORTHERN VIRGINIA
SAN ANTONIO
WASHINGTON, D.C.

ATTORNEYS AT LAW
590 MADISON AVENUE
NEW YORK, NEW YORK 10022
(212) 872-1000
FAX (212) 872-1002
www.akingump.com

DIRECT DIAL NUMBER 2 | 2-872-1016 E-MAIL ADDRESS nhumphreys@akingump.com

RIYADH (AFFILIATE)

November 19, 2001

#### Via Express Mail

Assistant Commissioner for Patents Washington, D.C. 20231

Re: Recordation of Patent Security Agreement

Ladies and Gentlemen:

We enclose herewith the following documents to be recorded in the Patent and Trademark Office: One cover sheet and one Patent Security Agreement.

You are hereby authorized to deduct \$2,120.00 from the Deposit Account # 50-1972 to cover the fee for recording the above referenced patent security agreement in respect of the 41 issued patents and 12 patent applications listed or referred to in the Patent Security Agreement.

If you have any questions, please do not hesitate to contact me directly at 212-872-1016.

Very truly yours,

Noel D. Humphreys

**Enclosures** 

cc:

Mr. Vivek Mehta Richard Cox, Esq.

EK753527495US

**RECORDED: 11/20/2001**